Chimerix, Inc.

NasdaqGM:CMRX Lagerbericht

Marktkapitalisierung: US$801.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Chimerix Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Chimerix hat ein Gesamteigenkapital von $121.7M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $146.0M bzw. $24.3M.

Wichtige Informationen

0%

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgradn/a
BargeldUS$131.64m
EigenkapitalUS$121.68m
GesamtverbindlichkeitenUS$24.33m
GesamtvermögenUS$146.01m

Jüngste Berichte zur Finanzlage

Analyseartikel • Jul 16

We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analyseartikel • Jul 20

Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • Dec 24

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analyseartikel • Sep 16

Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analyseartikel • Jun 08

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Recent updates

Seeking Alpha • Feb 20

Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients

Summary The company holds the potential to have the first approval of dordaviprone for the treatment of recurrent H3 K27M mutant high-grade glioma patients; PDUFA with a Priority Review date of August 18th, 2025. The global brain tumor therapeutics market is expected to grow to $5.28 billion by 2030; the Company notes that it could obtain >$1 billion in revenues in the United States alone. Phase 3 ACTION study using dordaviprone for the treatment of front-line H3 K27M mutant high-grade glioma patients to have OS interim data readout in Q3 of 2025. FDA approval of dordaviprone for the treatment of patients with recurrent H3 K27M mutant high-grade glioma could allow the company to receive a Priority Review Voucher, which it could keep or sell. Read the full article on Seeking Alpha
Seeking Alpha • Dec 11

Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy

Summary Chimerix, Inc.'s dordaviprone shows promise in treating H3 K27M-positive glioma, with a potential FDA approval and commercial launch by Q3 2025. CMRX's strong clinical data and high unmet need in diffuse midline glioma bolster confidence in FDA approval, despite potential timeline uncertainties. Financially, CMRX has a cash runway of 6–7 quarters, sufficient to reach an FDA decision, but risks of dilution remain. Given the recent market surge and promising outlook, I maintain a favorable rating on CMRX stock, anticipating significant market capitalization growth. Read the full article on Seeking Alpha
Analyseartikel • Jul 16

We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Aug 23

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Initiation of phase 3 ACTION study using ONC201 for treatment of glioma patients who harbor the H3 K27M mutation is expected in the 2nd half of 2022. Interim results from the ACTION study are expected in early 2025, with final results expected in 2026. Proof of concept data using ONC201 has already been established in two phase 2 studies; in patients with H3 K27M mutation gliomas and neuroendocrine tumors. Additional imipridones being developed in the pipeline are ONC206 and ONC212 for oncology indications; CMX521 being advanced as prophylactic and treatment for Covid-19. Chimerix, Inc. (CMRX) is a great speculative biotech that should be on your radar. While it is still a risky longer-term play, I believe it could have value based on established proof of concept using ONC201 for the treatment of patients with H3 K27M-mutant glioma. In a phase 2 study, it showed to improve overall survival rates in this specific population, which I will show below. The only downside is that the first interim analysis is not expected until early 2025 with final data not coming out until 2026. However, ONC201 is also being explored in a phase 2 study in neuroendocrine tumors. Such neuroendocrine tumors being explored are Pheochromocytoma/paraganglioma. Initial data was revealed which established some proof of concept of the mechanism of action. Even then, it is working on a second generation imipridone known as ONC206 which is much improved compared to 1st generation ONC201. It is believed that ONC206 provides greater anti-tumor activity compared to ONC201 and thus it is also being advanced in the pipeline. The biotech also entered into an agreement with Emergent BioSolutions ((EBS)) for the sale of worldwide rights to TEMBEXA for a $225 million upfront payment, potential milestone payments and double-digit royalties on net sales as well. It is important to note that this agreement is still in the process of being completed. This agreement relies on additional items being executed. If the agreement goes through with EBS, then the biotech will have enough cash into 2027. Lastly, it is in the process of developing an improved oral formulation of CMX521 as a prophylactic and treatment of SARS-CoV-2 (Covid-19) in collaboration with the Rapidly Emerging Antiviral Drug Development Initiative ((READDI)). While early in the process and already many approved treatments in this space, I believe it could still act as a catalyst if it is successfully advanced. It is believed that animal data will be released in the 2nd half of 2022 on such an improved oral formulation for CMX521 for Covid-19. With a growing pipeline, plus some established proof of concept of ONC201 in a rare brain glioma and neuroendocrine tumors, I believe it is a great speculative biotech play to look into. Imipridone ONC201 Could Possibly Greatly Improve Overall Survival Rates For Rare Gliomas The main drug in Chimerix's pipeline would be ONC201, which is being developed for the treatment of patients with gliomas who harbor the H3 K27M mutation. What occurs with respect to this specific type of glioma? What occurs is the H3K27M mutation itself puts in a new amino acid known as H3, which promotes a gene expression that enable tumor growth to occur. Patients with this type of glioma have poor prognosis and definitely need new types of treatments to be approved. Before diving into ONC201 clinical results, it's important to understand what the drug actually is. Again, it is an imipridone which targets G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease p (ClpP), resulting in cancer death. Cell death happens with the induction of the integrated stress response and upregulation pathway of apoptotic (cell death) factors, such as tumor necrosis factor ((TNF)) related apoptosis-inducing ligand ((TRAIL)). More specifically, it selectively induces cell death by binding and altering activity of DRD2 (Selectively coupled G-protein receptor) and ClpP. This is further established with the following action: DRD2 antagonism is responsible for inhibiting Ras signaling pathway that cancer has ClpP degrades excess amount of mitochondrial proteins which are important for the cancer cell to be viable Remember above when I stated that H3 K27M mutation uses amino acid H3 to promote gene expression for the cancer? Well, ONC201 was established to alter this gene expression making it sensitive to the drug itself. All these actions are what are put in place to specifically treat glioma patients who harbor the H3 K27M mutation. Moving onto the program advancement at hand, the company intends to initiate a phase 3 study in the 2nd half of 2022 known as ACTION. This is going to be a randomized late-stage study using ONC201 for the treatment of newly diagnosed diffuse glioma patients whose tumors harbor the H3 K27M mutation. It is expected that about 450 patients will be randomized 1:1:1 to receive doses as followed: 625 mg ONC201 once per week 625 mg ONC201 twice per week Placebo The primary endpoint of this study is overall survival ((OS)). Patients will first be treated with radiation and then be randomized to one of the dosing groups noted directly above. As far as catalysts go for this study, it could be quite some time to see data. It is said that the first interim analysis for results is not expected until 2025. From there, final data from this ACTION study is not expected until 2026. The thing is that it may be a good market to tap into despite the fact how rare the H3 K27M mutation glioma is. Chimerix believes it can earn above $500 million in sales annually should it ultimately get ONC201 to market for this specific population. Despite results taking time to come out, it's important to note that there is a great shot at clinical success. That's because ONC201 monotherapy was able to achieve an overall response rate ((ORR)) of 30% by RANO HGG and/or LGG by dual reader BICR. Even better, is what those treated with this drug obtained in terms of overall survival rates. For the H3 K27M recurrent glioma patients given ONC201, overall survival at 12 months and 24 months was 57% and 35%, respectively, whereas historical control at 12 months and 24 months was 27.5% and 6.4%, respectively. What does this show? This shows that with the biotech specifically targeting patients with this H3 K27M mutation by using ONC201, it can improve overall survival for them. Proof Of Concept For ONC201 In Treatment Of Patients With Neuroendocrine Tumors In addition to some proof of concept being established in a phase 2 study with ONC201 in patients with H3 K27M mutated gliomas, the drug had also seen some mechanism of action in patients with neuroendocrine tumors. One neuroendocrine tumor being explored is paraganglioma. A paraganglioma is a type of neuroendocrine tumor that forms near certain blood vessels and nerves outside of the adrenal glands. The adrenal glands being affects is not a very good thing, considering they are responsible for making hormones which control many functions in the body. In an open-label phase 2 investigator-initiated study with 30 patients, treatment with ONC201 performed pretty well. The cohort of paraganglioma patients who were dosed with ONC201 once a week performed better than the other cohort of patients dosed twice a week with ONC201. For these patients who were dosed once weekly with ONC201, the outcome was as follows: 5 out of 10 patients (50%) achieved a partial response ((PR)) 2 out of 10 patients achieved stable disease ((SD)) The other neuroendocrine tumor also being evaluated with the use of this drug is Pheochromocytoma, which is a hormone secreting tumor that can occur in the adrenal glands. Additional Shots On Goal With Imipridones ONC206 And ONC212
Analyseartikel • Jul 20

Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jun 06

Chimerix: Down But Not Out

Today, we revisit an interesting small-cap concern called Chimerix that trades for around two bucks a share, and under cash value. The company recently announced a deal to sell off its one approved drug for over $200 million, which was received negatively by the market. Chimerix will now pivot fully to developing the other parts of its pipeline. We revisit the investment case around Chimerix in the paragraphs below.
Seeking Alpha • Jan 05

Chimerix: Searching For Clarity

Today, we put Chimerix, Inc. in the spotlight for the first time. The company recently received an FDA approval and has several other promising compounds in development. A full investment analysis is provided in the paragraphs below.
Analyseartikel • Dec 24

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analyseartikel • Sep 16

Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analyseartikel • Jun 08

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analyseartikel • May 13

Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?

With the business potentially at an important milestone, we thought we'd take a closer look at Chimerix, Inc.'s...

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: CMRXDie kurzfristigen Aktiva des Unternehmens ($136.0M) übersteigen seine kurzfristigen Passiva ($23.9M).

Langfristige Verbindlichkeiten: CMRXDie kurzfristigen Vermögenswerte des Unternehmens ($136.0M) übersteigen seine langfristigen Verbindlichkeiten ($458.0K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: CMRX ist schuldenfrei.

Schulden abbauen: CMRX hat seit wenigstens 5 Jahren keine Schulden.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: CMRX auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: CMRX verfügt über eine ausreichende Liquiditätsreserve für 1.7 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 2.6% pro Jahr abnimmt.

Entdecken Sie finanziell stabile Unternehmen

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2025/04/22 19:50
Aktienkurs zum Tagesende2025/04/17 00:00
Gewinne2024/12/31
Jährliche Einnahmen2024/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Chimerix, Inc. wird von 15 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Geoffrey MeachamBarclays
Debjit ChattopadhyayBrean Capital Historical (Janney Montgomery)
Ritu BaralCanaccord Genuity